Abiprubart

DB19333InvestigationalProtein Based Therapies

Abiprubart is being evaluated for its efficacy and safety in participants with Sjögren's Disease in clinical trial NCT06531395.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 5
Curator reviewed
Also known as: Gamma4 heavy chain humanized (1-441) [VH (Homo sapiens IGHV1-3*01 (83.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.7] (26-33.51-58.97-103)) (1-114)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10 (CH1 (115-212), hinge 1-12 S10>P (222) (213-224), CH2 L · Immunoglobulin G4 [222-proline], anti-(human CD40 antigen) (human-Mus musculus monoclonal KPL-404 γ4-chain), disulfide with human-Mus musculus monoclonal KPL-404 κ-chain, dimer · Immunoglobulin G4-kappa, anti-[Homo sapiens CD40 (TNFRSF5, tumor necrosis factor receptor (TNFR) superfamily member 5, p50)], humanized monoclonal antibody
Code names: KPL-404

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Abiprubart, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.